1.5.1.33	gtp cyclohydrolase i deficiency	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31202265&form=6&db=m	GTP-Cyclohydrolase I deficiency presenting as malignant hyperphenylalaninemia, recurrent hyperthermia and progressive neurological dysfunction in a South Asian child - a case report.	causal interaction,diagnostic usage,therapeutic application,unassigned	4,3,1,0	
1.5.1.33	Leishmaniasis	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19916554&form=6&db=m	Structure-based design of pteridine reductase inhibitors targeting African sleeping sickness and the leishmaniases.	therapeutic application,unassigned	3,0	
1.5.1.33	Leishmaniasis	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31370699&form=6&db=m	Targeting pteridine reductase 1 and dihydrofolate reductase: the old is a new trend for leishmaniasis drug discovery.	therapeutic application,unassigned	4,0	
1.5.1.33	Leishmaniasis	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31702401&form=6&db=m	Structure based designing of benzimidazole/benzoxazole derivatives as anti-leishmanial agents.	therapeutic application,unassigned	4,0	
1.5.1.33	Leishmaniasis, Visceral	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21115787&form=6&db=m	In silico screening, structure-activity relationship, and biologic evaluation of selective pteridine reductase inhibitors targeting visceral leishmaniasis.	causal interaction,therapeutic application,unassigned	2,4,0	
1.5.1.33	pteridine reductase deficiency	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=691345&form=6&db=m	[Pteridine reductase deficiency]	causal interaction,unassigned	4,0	
1.5.1.33	Trypanosomiasis, African	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16968221&form=6&db=m	Structure and reactivity of Trypanosoma brucei pteridine reductase: inhibition by the archetypal antifolate methotrexate.	therapeutic application,unassigned	4,0	
1.5.1.33	Trypanosomiasis, African	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19527033&form=6&db=m	One scaffold, three binding modes: novel and selective pteridine reductase 1 inhibitors derived from fragment hits discovered by virtual screening.	therapeutic application,unassigned	4,0	
1.5.1.33	Trypanosomiasis, African	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19916554&form=6&db=m	Structure-based design of pteridine reductase inhibitors targeting African sleeping sickness and the leishmaniases.	therapeutic application,unassigned	3,0	
1.5.1.33	Trypanosomiasis, African	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27485569&form=6&db=m	Pharmacophore Mapping, In Silico Screening and Molecular Docking to Identify Selective Trypanosoma brucei Pteridine Reductase Inhibitors.	therapeutic application,unassigned	2,0